Michael Bitzer on Muck Rack

Michael Bitzer

As seen in: Nature, Post Outlook, The Washington Post, The Hill, La Tercera, Science Magazine, Newsday, The Charlotte Observer, Mary Ann Liebert, Inc., Salisbury Post and
original posts at bsky.app/profile/bowtiepolitics.bsky.social. here: mostly RTs
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michael

Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial

|
By Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, Jorge Riera-Knorrenschild, Eray Goekkurt, Tobias Dechow, Thomas Ettrich, Ralf Dieter Hofheinz, Kim Barbara Luley, Daniel H. Pink, Udo Lindig, Gunnar Folprecht, Gunter Schuch, Michael Bitzer, Volker Heinemann, Stefan Angermeier, Claus Bolling, Maria Loose, Sabine Junge, Claudia Pauligk, Salah-Eddin Al-Batran
| Nature Verified
Correction to: Nature Communications https://doi.org/10.1038/s41467-026-69622-7, published online 27 February 2026 In the version of this article initially published, funding information did not acknowledge the sponsor of the trial is the Frankfurt Institute of Clinical Cancer Research IKF GmbH and that financial support and drug supply for the conduct of the trial was granted by Bristol-Myers Squibb GmbH & Co. KGaA, while the title was incomplete and did not reference the Institut für...
Open in Who Shared Issue with article?

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial | Nature Communications

|
By Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, Jorge Riera-Knorrenschild, Eray Goekkurt, Tobias Dechow, Thomas Ettrich, Ralf Dieter Hofheinz, Kim Barbara Luley, Daniel H. Pink, Gunnar Folprecht, Michael Bitzer, Volker Heinemann, Maria Loose, Sabine Junge, Claudia Pauligk, Salah-Eddin Al-Batran, Udo Lindig, Gunter Schuch, Stefan Angermeier, Claus Bolling
| Nature Verified
Abstract This multi-cohort study evaluates whether dual immune checkpoint inhibition with nivolumab and ipilimumab in parallel or sequentially, or triplet chemotherapy with nivolumab can enhance efficacy as first-line therapy for advanced or metastatic gastroesophageal adenocarcinoma. Patients are randomized 1:1 to Arm A (mFOLFOX + nivolumab 240 mg every two weeks + ipilimumab 1 mg/kg every six weeks in parallel or Arm B (mFOLFOX).
Open in Who Shared Issue with article?

Personalized signaling pathway analysis of gastrointestinal tumors for patient stratification and drug target evaluation using clinically derived core biopsies | npj Precision Oncology

|
By Aaron Stahl, Sven Mattern, Stephan Singer Verified, Nisar P. Malek, Katja Schenke-Layland, Michael Bitzer, Markus Templin, Karsten Büringer, Pavlos Missios, Tatjana Hoffmann, Felix Schäfer-Ruoff
| Nature Verified
Abstract Aberrant cellular signaling underlies cancer development and progression. Identifying alterations in these pathways yields critical insights for personalized oncology. Clinically, assessing the activation status of signaling proteins complements genetic and histopathological analyses, improving therapeutic evaluation and accuracy.
Open in Who Shared Issue with article?
See all 82 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified